Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia (CML)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 0 results

Early research (Phase 1)Study completedNCT00816283
What this trial is testing

Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

Who this might be right for
Leukemia
City of Hope Medical Center 5
Early research (Phase 1)Study completedNCT00316953
What this trial is testing

Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaBlastic Phase Chronic Myelogenous LeukemiaChildhood Chronic Myelogenous Leukemia+5 more
National Cancer Institute (NCI) 48
Not applicableStudy completedNCT00068523
What this trial is testing

Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+3 more
Case Comprehensive Cancer Center 10
Testing effectiveness (Phase 2)Study completedNCT00390793
What this trial is testing

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

Who this might be right for
Acute Lymphoblastic LeukemiaBCR-ABL1 Fusion Protein ExpressionBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+3 more
M.D. Anderson Cancer Center 107
Testing effectiveness (Phase 2)Study completedNCT00244829
What this trial is testing

Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia

Who this might be right for
Leukemia
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT04188405
What this trial is testing

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Myeloid LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+4 more
M.D. Anderson Cancer Center 20
Not applicableStudy completedNCT03647215
What this trial is testing

CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey

Who this might be right for
Chronic Phase Chronic Myelogenous LeukemiaAccelerated Phase Chronic Myelogenous LeukemiaBlastic Phase Chronic Myelogenous Leukemia+1 more
Incyte Biosciences UK 427
Testing effectiveness (Phase 2)UnknownNCT00008307
What this trial is testing

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
Herbert Irving Comprehensive Cancer Center 52
Testing effectiveness (Phase 2)Study completedNCT02311998
What this trial is testing

Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML

Who this might be right for
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlasts More Than 5 Percent of Bone Marrow Nucleated Cells+4 more
M.D. Anderson Cancer Center 22